Vertex Pharmaceuticals IncorporatedVRTXNASDAQ

Overview Intelligence Charts News Fundamentals

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating

Buy

27 analysts·High coverage

85%

Rating Distribution

Strong Buy

00%

Buy

2385%

Hold

415%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 16% higher.

Bear Case

$441.00

-7%

Consensus

$549.31

+16%

Bull Case

$607.00

+28%

Price Range27 analysts

Low

Consensus

High

$441.00

$607.00

Current Target

Current Price

$474.27

Upside to Target

$75.04

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$19.35(19 analysts)

P/E30x

Current: 30.5x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+10.00%

EPS+14.43%

FY2028

Rev+10.12%

EPS+8.74%

FY2029

Rev+11.40%

EPS+19.74%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+1.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 2, 2026BMO Capital

Vertex (VRTX) PT Raised to $600 at BMO Capital

Target:$600.00

+23.1%from $487.57

Feb 17, 2026Canaccord Genuity

Vertex Pharmaceuticals price target raised to $441 from $411 at Canaccord

Target:$441.00

-10.3%from $491.47

Feb 17, 2026Barclays

Vertex Pharmaceuticals price target raised to $607 from $606 at Barclays

Target:$607.00

+23.5%from $491.47

Feb 17, 2026H.C. Wainwright

Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright

Target:$591.00

+20.3%from $491.47

Feb 13, 2026Morgan Stanley

Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley

Target:$570.00

+14.6%from $497.42

Feb 13, 2026Scotiabank

Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank

Target:$558.00

+13.0%from $493.98

Feb 13, 2026RBC Capital

Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital

Target:$541.00

+9.1%from $496.02

Feb 13, 2026Bernstein

Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein

Target:$577.00

+16.0%from $497.21

Feb 13, 2026Cantor Fitzgerald

Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald

Target:$590.00

+19.2%from $495.11

Feb 13, 2026Stifel Nicolaus

Vertex Pharmaceuticals price target raised to $466 from $445 at Stifel

Target:$466.00

+0.2%from $465.02

Feb 13, 2026H.C. Wainwright

Vertex Pharmaceuticals price target raised to $518 from $478 at H.C. Wainwright

Target:$518.00

+11.4%from $465.02

Jan 27, 2026Barclays

Vertex Pharmaceuticals assumed with Overweight from Equal Weight at Barclays

Target:$606.00

+27.8%from $474.17

Jan 26, 2026UBS

Vertex Pharmaceuticals price target raised to $545 from $535 at UBS

Target:$545.00

+15.0%from $474.09

Jan 23, 2026Evercore ISI

Vertex Pharmaceuticals price target raised to $530 from $475 at Evercore ISI

Target:$530.00

+13.0%from $469.11

Jan 22, 2026RBC Capital

Vertex upgraded to Outperform from Sector Perform at RBC Capital

Target:$546.00

+18.4%from $461.14

Jan 6, 2026UBS

Vertex Pharmaceuticals assumed with a Buy at UBS

Target:$535.00

+14.2%from $468.38

Dec 29, 2025Leerink Partners

Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink

Target:$525.00

+13.6%from $462.12

Dec 5, 2025Morgan Stanley

Vertex Pharmaceuticals price target raised to $564 from $516 at Morgan Stanley

Target:$564.00

+22.2%from $461.48

Dec 3, 2025Morgan Stanley

Vertex upgraded to Overweight from Equal Weight at Morgan Stanley

Target:$516.00

+19.1%from $433.15

Nov 4, 2025RBC Capital

Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital

Target:$415.00

-2.8%from $426.93

Nov 4, 2025Cantor Fitzgerald

Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)

Target:$485.00

+13.5%from $427.30

Nov 4, 2025Stifel Nicolaus

Vertex Pharmaceuticals price target lowered to $445 from $455 at Stifel

Target:$445.00

+4.5%from $426.00

Nov 4, 2025Barclays

Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays

Target:$414.00

-2.8%from $426.00

Oct 10, 2025Morgan Stanley

Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley

Target:$438.00

+5.8%from $413.93

Sep 25, 2025Leerink Partners

Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth

Target:$456.00

+19.4%from $381.87

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance